Cell therapy

Notch Therapeutics – a new company with a revolutionary allogeneic ("off the shelf") T cell technology

Retrieved on: 
Tuesday, November 5, 2019
Stem cells, Biotechnology, Cell biology, Cell therapy, Uot, Notch

"Finally having optionstotarget these high-impact areasfor our patientsis what we mean when we say we are inventing the future of health care."

Key Points: 
  • "Finally having optionstotarget these high-impact areasfor our patientsis what we mean when we say we are inventing the future of health care."
  • Jennifer Fraser, Director Innovations at the University of Toronto, comments that "Dr. Ziga-Pflckers allogeneic T cell therapy was one of the first projects I worked on when I joined UoT.
  • The Notch technology, however, shows promise for surmounting these issues cost-effectively and reliably.
  • "Notch Therapeutics is a star pupil in CCRMs incubation program," says Dr. Michael May, President and CEO of CCRM.

ReNeuron Presents Positive Data at the 27th Annual Congress of the European Society of Gene and Cell Therapy on Lead Cell Line

Retrieved on: 
Wednesday, October 23, 2019
Branches of biology, Biology, Life sciences, Stem cells, Stem-cell therapy, Stem-cell line, Mesenchymal stem cell, Cell therapy, Neural stem cell, Induced stem cells, Royan Institute

Dr. Steve Pells, Principal Investigator at ReNeuron, will present new data showing the phenotypic stability and scalability of a mesenchymal stem cell line derived from the Company's proprietary, conditionally immortalized, human neural stem cell line (CTX) following re-programming to a pluripotent state.

Key Points: 
  • Dr. Steve Pells, Principal Investigator at ReNeuron, will present new data showing the phenotypic stability and scalability of a mesenchymal stem cell line derived from the Company's proprietary, conditionally immortalized, human neural stem cell line (CTX) following re-programming to a pluripotent state.
  • Further, the mesenchymal stem cell lines generated can be grown at scale by virtue of the Company's conditional immortalization technology, enabling the efficient production of clinical-grade cell therapy candidates.
  • non-donor-specific) cell lines from any of the three primary germ cell layers which form during embryonic development.
  • ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop 'off the shelf' stem cell treatments, without the need for immunosuppressive drugs.

Lineage Cell Therapeutics to Present at Dawson James Securities 5th Annual Small Cap Growth Conference on October 29, 2019

Retrieved on: 
Tuesday, October 22, 2019
Biotechnology, Health, Stem cells, Optical, Clinical trials, Branches of biology, Biology, Life sciences, Stem cells, Biotechnology, Induced stem cells, Developmental biology, Cell biology, Cellular differentiation, Cell therapy, New York Stem Cell Foundation

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs.

Key Points: 
  • Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs.
  • Lineages programs are based on its proprietary cell-based therapy platform and associated development and manufacturing capabilities.
  • With this platform Lineage develops and manufactures specialized, terminally-differentiated human cells from its pluripotent and progenitor cell starting materials.
  • Lineage is also evaluating potential partnership opportunities for Renevia, a facial aesthetics product that was recently granted a Conformit Europenne (CE) Mark.

Orgenesis Announces Co-Development Agreement with Accellix

Retrieved on: 
Wednesday, October 16, 2019
Biology, Natural sciences, Life sciences, Stem cells, Biotechnology, Assay, Biochemistry, Titration, Cell therapy

The agreement will enable Orgenesis to integrate Accellixs proprietary optic system, cartridges, reagents and software into Orgenesis Point of Care (POCare) cellular therapy processing services and platform.

Key Points: 
  • The agreement will enable Orgenesis to integrate Accellixs proprietary optic system, cartridges, reagents and software into Orgenesis Point of Care (POCare) cellular therapy processing services and platform.
  • Orgenesis POCare cell therapy platform has been specifically designed to collect, process and supply cells within the patient care location for various therapeutic treatments.
  • The Accellix assay delivery platform advances the quality control aspects of Orgenesis POCare platform by providing actionable multi-parameter results for analyzing and processing live cells.
  • Vered Caplan, CEO of Orgenesis, stated, By partnering with Accellix and integrating its advanced optic technologies, cartridges and software, we believe that this will advance Orgenesis processing capabilities for different types of cells for our POCare services and platform.

AgeX Therapeutics to Present at Metabesity 2019

Retrieved on: 
Friday, October 11, 2019
Stem cells, Science, Biotechnology, Pharmaceutical, Research, Health, Branches of biology, Biology, Life sciences, Biotechnology, Cell biology, Stem cells, Cloning, Developmental biology, Cell therapy, T cell, Progenitor cell

AgeX has two preclinical cell therapy programs: AGEX-VASC1 (vascular progenitor cells) for tissue ischemia and AGEX-BAT1 (brown fat cells) for Type II diabetes.

Key Points: 
  • AgeX has two preclinical cell therapy programs: AGEX-VASC1 (vascular progenitor cells) for tissue ischemia and AGEX-BAT1 (brown fat cells) for Type II diabetes.
  • AgeXs revolutionary longevity platform named induced Tissue Regeneration (iTR) aims to unlock cellular immortality and regenerative capacity to reverse age-related changes within tissues.
  • HyStem is AgeXs delivery technology to stably engraft PureStem cell therapies and slowly release iTR molecules in the body.
  • Certain statements contained in this release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

City of Hope Is Enrolling Patients in First of Its Kind Clinical Trial for Brain Tumor Patients

Retrieved on: 
Wednesday, October 9, 2019
FDA, Stem cells, Pharmaceutical, Oncology, General Health, Genetics, Clinical trials, Science, Biotechnology, Research, Health, Branches of biology, Medicine, Clinical medicine, Cancer treatments, Stem cells, Biotechnology, Transplantation medicine, Cell biology, Immunotherapy, Chimeric antigen receptor T cell, Hematopoietic stem cell transplantation, Cell therapy

The trial will deliver CAR T cells that target IL13R2 locally to the brain, by direct injection to the tumor site and through infusion into the ventricular system.

Key Points: 
  • The trial will deliver CAR T cells that target IL13R2 locally to the brain, by direct injection to the tumor site and through infusion into the ventricular system.
  • City of Hope was the first to use this type of delivery for glioblastoma patients receiving CAR T treatment, as well as the first to investigate CAR T cells targeting IL13R2.
  • Mustang Bio Inc. (NASDAQ: MBIO) is the exclusive licensee of City of Hope patents covering its IL13R2-specific CAR T cell therapy.
  • Founded in 1913, City of Hope is a leader in bone marrow transplantation and immunotherapy such as CAR T cell therapy .

Global Cell Therapy Technologies, Companies & Markets During the Forecast Period, 2018-2028 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, October 9, 2019
Pharmaceutical, Health, Stem cells, Branches of biology, Life sciences, Biology, Biotechnology, Emerging technologies, Stem cells, Medical genetics, Molecular biology, Therapy, Gene therapy, Cell therapy, Stem-cell therapy

The "Cell Therapy - Technologies, Markets and Companies" report from Jain PharmaBiotech has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cell Therapy - Technologies, Markets and Companies" report from Jain PharmaBiotech has been added to ResearchAndMarkets.com's offering.
  • This report describes and evaluates cell therapy technologies and methods, which have already started to play an important role in the practice of medicine.
  • Cell therapy technologies overlap with those of gene therapy, cancer vaccines, drug delivery, tissue engineering and regenerative medicine.
  • Safety is an essential consideration of any new therapy and regulations for cell therapy are those for biological preparations.

Stem Cells Market to Gain Huge Traction Owing to Arrival of New-Fangled Treatments for Long-Lasting Sicknesses Till 2025 | Million Insights

Retrieved on: 
Monday, October 7, 2019
Branches of biology, Biology, Life sciences, Stem cells, Biotechnology, Cell biology, Emerging technologies, Stem-cell therapy, Adult stem cell, Cell therapy, Induced pluripotent stem cell, Stem-cell line

A substantial growth in the number of clinical use of stem cells and the arrival of new-fangled treatments for long-lasting sicknesses are projected to boost the development of the global stem cells market during the following insufficient years.

Key Points: 
  • A substantial growth in the number of clinical use of stem cells and the arrival of new-fangled treatments for long-lasting sicknesses are projected to boost the development of the global stem cells market during the following insufficient years.
  • By Therapy it can be classified as Allogeneic Stem Cell Therapy, Autologous Stem Cell Therapy.
  • By Product it can be classified as Very Small Embryonic like Stem Cells, Human Embryonic, Induced Pluripotent Stem Cells, and Adult Stem Cells.
  • Browse 190 page research report with TOC on "Global Stem Cells Market" at: https://www.millioninsights.com/industry-reports/stem-cells-market
    Stem Cell Product Outlook (Revenue, USD Billion, 2014 - 2025)

Stem Cells Market to Gain Huge Traction Owing to Arrival of New-Fangled Treatments for Long-Lasting Sicknesses Till 2025 | Million Insights

Retrieved on: 
Monday, October 7, 2019
Branches of biology, Biology, Life sciences, Stem cells, Biotechnology, Cell biology, Emerging technologies, Stem-cell therapy, Adult stem cell, Cell therapy, Induced pluripotent stem cell, Stem-cell line

A substantial growth in the number of clinical use of stem cells and the arrival of new-fangled treatments for long-lasting sicknesses are projected to boost the development of the global stem cells market during the following insufficient years.

Key Points: 
  • A substantial growth in the number of clinical use of stem cells and the arrival of new-fangled treatments for long-lasting sicknesses are projected to boost the development of the global stem cells market during the following insufficient years.
  • By Therapy it can be classified as Allogeneic Stem Cell Therapy, Autologous Stem Cell Therapy.
  • By Product it can be classified as Very Small Embryonic like Stem Cells, Human Embryonic, Induced Pluripotent Stem Cells, and Adult Stem Cells.
  • Browse 190 page research report with TOC on "Global Stem Cells Market" at: https://www.millioninsights.com/industry-reports/stem-cells-market
    Stem Cell Product Outlook (Revenue, USD Billion, 2014 - 2025)

ViaCyte to Present Preliminary PEC-Direct Clinical Data at Cell & Gene Meeting on the Mesa

Retrieved on: 
Thursday, October 3, 2019
Branches of biology, Biology, Life sciences, Stem cells, Biotechnology, Induced stem cells, Cell biology, Regenerative biomedicine, Stem-cell line, Regenerative medicine, Cell therapy

SAN DIEGO, Oct. 3, 2019 /PRNewswire/ -- ViaCyte, Inc. , a privately-held regenerative medicine company, will present preliminary data today from the company's PEC-Direct clinical trialat the Cell & Gene Meeting on the Mesa taking place in Carlsbad, California.

Key Points: 
  • SAN DIEGO, Oct. 3, 2019 /PRNewswire/ -- ViaCyte, Inc. , a privately-held regenerative medicine company, will present preliminary data today from the company's PEC-Direct clinical trialat the Cell & Gene Meeting on the Mesa taking place in Carlsbad, California.
  • These data show that our PEC-01 cells are functioning as intended when appropriately engrafted," said Paul Laikind, Ph.D., Chief Executive Officer and President of ViaCyte.
  • We plan to present additional data in the near future."
  • ViaCyte is also developing immune-evasive stem cell lines, from its proprietary CyT49 cell line, which have the potential to further broaden the availability of cell therapy for diabetes and other potential indications.